Ascendia

  MARKET NEWS

Can-Fite Achieves Milestone With First Patient Dosing in Pancreatic Cancer Phase 2a Clinical Trial
CERo Therapeutics Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity
Transgene & NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine in Head & Neck Cancer
Lonza’s Synaffix Collaborates With BigHat Biosciences on the Development of a Machine Learning-Designed ADC
Adipo Therapeutics Presents Positive Study Results About Potential Obesity Treatment
Tilray Medical Announces Positive Results From Study on Oral Cannabis Extract for Chemotherapy-Induced Emesis
Palisade Bio Announces First Subject Dosed in Phase 1 Study for Moderate-to-Severe Ulcerative Colitis Treatment
Palvella Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial for Microcystic Lymphatic Malformations Treatment
Bespak & Orbia Fluor & Energy Materials Unite to Accelerate Transition to Climate-Friendly Inhalers
SGS Expands Cutting-Edge Spray Drug Delivery Testing Capabilities in Belgium Health Science Laboratory

  EXPERT CONTENT & RESOURCES

On-Demand Presentation: High Concentration Protein Suspensions: A Bevacizumab Case Study (>400 mg/mL)

On-Demand Presentation: High Concentration Protein Suspensions: A Bevacizumab Case Study (>400 mg/mL)

Dr. Cindy Chung presents a case study demonstrating the development of high concentration bevacizumab suspension at up to 400 mg/mL for suitable subcutaneous delivery of the monoclonal antibody (mAb) therapy. Watch the presentation now to learn more.

DRUG-DEVICE DEVELOPMENT - Exploring the Complexities of Drug-Device Combination Products

DRUG-DEVICE DEVELOPMENT - Exploring the Complexities of Drug-Device Combination Products

Jeremy Guo, Senior Vice President at WuXi Biologics, and colleagues explain that many factors need to be taken into account when producing a Drug-Device Combination Product from development testing to fill/finish and assembly.

  FEATURED EDITORIAL

  COMPANY PROFILE

With over 4300 customer-centric employees and commercial operations across the US, EU and China, Porton J-STAR provides pharmaceutical and biotech companies with innovative, reliable and end-to-end process R&D and GMP manufacturing services for Drug Substance and Drug Product across Small Molecules, Tides, Biologics and Conjugates. Porton J-STAR is recognized for our process innovation, supply chain performance and compliance with global Quality and EHS standards. Constantly striving for excellence and enabling the public’s early access to good medicines. Click here for more.

Click image to watch Lifecore Biomedical’s latest video

  WHITEPAPERS & WEBINARS

WEBINAR: Introducing Key Concepts in Tableting Research: Unleashing Essential Concepts and Strategies for Enhanced Formulation Development

WEBINAR: Introducing Key Concepts in Tableting Research: Unleashing Essential Concepts and Strategies for Enhanced Formulation Development

Tableting can present a series of challenges, particularly when dealing with formulations that have poor flowability, low compressibility, or high cohesivity. These issues can lead to manufacturing inefficiencies….

  WHITEPAPERS & WEBINARS

WHITEPAPER - Concept to Commercialization: The Role of CDMOs in Driving Innovation Through Phase-Appropriate Technology Transfers

WHITEPAPER - Concept to Commercialization: The Role of CDMOs in Driving Innovation Through Phase-Appropriate Technology Transfers

CDMOs are emerging as critical drivers of innovation within the pharmaceutical and biotech industries. As the pharmaceutical industry continues to evolve, we can expect to see CDMOs play an increasingly important role in drug development and manufacturing. Many companies within …

Technical Brief: Mucoadhesive Polymers in Pharmaceutical Formulations

Technical Brief: Mucoadhesive Polymers in Pharmaceutical Formulations

Mucoadhesion Matters

And so does your choice of mucoadhesive polymer.

This technical brief will cover the use of polymers in a variety of dosage forms (buccal/sublingual tablets, liquid, semi-solid formulations, and oral care products) to impart mucoadhesion. The basic mechanism …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

November 20 – Particle Design Technology
November 27 – Bioavailability